Literature DB >> 20858449

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.

Jeremy D Gates1, Guy T Clifton, Linda C Benavides, Alan K Sears, Mark G Carmichael, Matthew T Hueman, Jarrod P Holmes, Yusuf H Jama, Mohamed Mursal, Athina Zacharia, Kathy Ciano, Steven Khoo, Alexander Stojadinovic, Sathibalan Ponniah, George E Peoples.   

Abstract

Regulatory T cells (T(Reg)), CD4(+)CD25(+)FOXP3(+), are implicated in suppressing tumor immune responses. We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for T(Reg) cells and correlated their levels with vaccine-specific immune responses. The mean CD4(+)CD25(+)FOXP3(+) T(Reg) cells decreased in patients with vaccination with no significant difference in serum TGF-β levels. IFN-γ ELISPOT and DTH increased after vaccination with a good correlation between T(Reg) cell reduction and size of DTH to AE37. The T(Reg) cell reduction and associated immune response suggest that AE37 may be clinically useful.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20858449     DOI： 10.1016/j.vaccine.2010.09.029

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  The dual role of the X-linked FoxP3 gene in human cancers.

Authors:  Margaret Redpath; Bin Xu; Leon C van Kempen; Alan Spatz
Journal:  Mol Oncol       Date:  2011-03-30       Impact factor: 6.603

Review 2.  Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Authors:  Leisha A Emens
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

3.  Monitoring regulatory immune responses in tumor immunotherapy clinical trials.

Authors:  Brian M Olson; Douglas G McNeel
Journal:  Front Oncol       Date:  2013-05-06       Impact factor: 6.244

4.  A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Napolitano; Antonio Luciano; Domenica Rea; Antonio Barbieri; Claudio Arra; Piera Maiolino; Marialina Tornesello; Gennaro Ciliberto; Franco M Buonaguro; Luigi Buonaguro
Journal:  J Transl Med       Date:  2016-02-24       Impact factor: 5.531

Review 5.  Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.

Authors:  Nehad M Ayoub; Kamal M Al-Shami; Rami J Yaghan
Journal:  Breast Cancer (Dove Med Press)       Date:  2019-01-17

6.  Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.

Authors:  Tommy A Brown; Elizabeth A Mittendorf; Diane F Hale; John W Myers; Kaitlin M Peace; Doreen O Jackson; Julia M Greene; Timothy J Vreeland; G Travis Clifton; Alexandros Ardavanis; Jennifer K Litton; Nathan M Shumway; J Symanowski; James L Murray; Sathibalan Ponniah; E A Anastasopoulou; N F Pistamaltzian; Constantin N Baxevanis; Sonia A Perez; Michael Papamichail; George E Peoples
Journal:  Breast Cancer Res Treat       Date:  2020-04-22       Impact factor: 4.872

Review 7.  Breast Cancer Vaccines: Disappointing or Promising?

Authors:  Si-Yuan Zhu; Ke-Da Yu
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

8.  Analysis of the Heterogeneity of CD4+CD25+ T Cell TCR β CDR3 Repertoires in Breast Tumor Tissues, Lung Metastatic Tissues, and Spleens from 4T1 Tumor-Bearing BALB/c Mice.

Authors:  Teng Zhang; Fangfang Duan; Danhua Su; Long Ma; Jiezuan Yang; Bin Shi; Xiaoyan He; Rui Ma; Suhong Sun; Xinsheng Yao
Journal:  J Immunol Res       Date:  2020-09-24       Impact factor: 4.818
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.